{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:34:18Z","timestamp":1780630458815,"version":"3.54.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.anai.2012.02.021","type":"journal-article","created":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T03:03:33Z","timestamp":1332299013000},"page":"383-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab"],"prefix":"10.1016","volume":"108","author":[{"given":"Matthew C.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2012.02.021_bib1","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2012.02.021_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-4-10","article-title":"Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options","volume":"4","author":"Molderings","year":"2011","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.anai.2012.02.021_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1365-2249.2010.04287.x","article-title":"Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay","volume":"163","author":"Sargur","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.anai.2012.02.021_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2169\/internalmedicine.50.4640","article-title":"Omalizumab treatment of systemic mast cell activation disease: experiences from four cases","volume":"50","author":"Molderings","year":"2011","journal-title":"Intern Med"},{"key":"10.1016\/j.anai.2012.02.021_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1398-9995.2009.02259.x","article-title":"Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient","volume":"65","author":"Douglass","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2012.02.021_bib6","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2012.02.021_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2006.04.005","article-title":"Anti-IgE as a mast cell-stabilizing therapeutic agent","volume":"117","author":"Chang","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2012.02.021_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","article-title":"Differential release of mast cell mediators and the pathogenesis of inflammation","volume":"217","author":"Theoharides","year":"2007","journal-title":"Immunol Rev"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120612001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120612001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:07:09Z","timestamp":1761052029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120612001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1081120612001457"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2012.02.021","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2012.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}